Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Toward a Cure: Does Host Immunity Play a Role?

Zhang J, Crumpacker CS.

mSphere. 2017 Apr 26;2(2). pii: e00138-17. doi: 10.1128/mSphere.00138-17. eCollection 2017 Mar-Apr.

2.

Hematopoietic Stem and Immune Cells in Chronic HIV Infection.

Zhang J, Crumpacker C.

Stem Cells Int. 2015;2015:148064. doi: 10.1155/2015/148064. Epub 2015 Aug 2. Review.

3.

Eradication of HIV and Cure of AIDS, Now and How?

Zhang J, Crumpacker C.

Front Immunol. 2013 Oct 18;4:337. doi: 10.3389/fimmu.2013.00337. Review.

4.

Naive and memory CD4⁺ T cells in HIV eradication and immunization.

Zhang J, Poznansky M, Crumpacker C.

J Infect Dis. 2012 Aug 15;206(4):617-8; author reply 618. doi: 10.1093/infdis/jis387. Epub 2012 Jun 13. No abstract available.

PMID:
22696498
5.

Absence of exposure to varicella does not increase the risk of zoster.

Crumpacker CS 2nd.

Clin Infect Dis. 2011 Sep;53(5):411-2. doi: 10.1093/cid/cir439. No abstract available.

PMID:
21844023
6.

Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM.

J Infect Dis. 2011 May 15;203(10):1434-41. doi: 10.1093/infdis/jir047. Epub 2011 Apr 14. Erratum in: J Infect Dis. 2011 Aug;204(3):492.

7.

Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity.

Chunduri H, Crumpacker C, Sharma PL.

Virology. 2011 May 25;414(1):34-41. doi: 10.1016/j.virol.2011.03.007. Epub 2011 Apr 2.

9.

Invited commentary: human cytomegalovirus, inflammation, cardiovascular disease, and mortality.

Crumpacker CS.

Am J Epidemiol. 2010 Aug 15;172(4):372-4. doi: 10.1093/aje/kwq174. Epub 2010 Jul 21.

PMID:
20660119
10.

Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution.

Zhang J, Crumpacker CS.

Cell Res. 2010 Jul;20(7):745-7. doi: 10.1038/cr.2010.85. Epub 2010 Jun 22. No abstract available.

PMID:
20567263
11.

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.

PMID:
19648823
12.

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team.

HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143.

13.

Cytomegalovirus infection causes an increase of arterial blood pressure.

Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, Zhang J, Crumpacker CS.

PLoS Pathog. 2009 May;5(5):e1000427. doi: 10.1371/journal.ppat.1000427. Epub 2009 May 15.

14.

Valganciclovir and human herpesvirus-8.

Crumpacker CS.

J Infect Dis. 2008 Jul 1;198(1):6-7. doi: 10.1086/588821. No abstract available.

PMID:
18491975
15.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

PMID:
17721395
16.

Primitive hematopoietic cells resist HIV-1 infection via p21.

Zhang J, Scadden DT, Crumpacker CS.

J Clin Invest. 2007 Feb;117(2):473-81.

17.

Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis.

Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zhang J, Chu V, Hampton TG, Crumpacker CS, Abelmann WH, Amende I, Morgan JP.

Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1577-83. Epub 2005 May 27.

18.

Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells.

Zhang J, Attar E, Cohen K, Crumpacker C, Scadden D.

Gene Ther. 2005 Oct;12(19):1444-52.

PMID:
15877047
19.

Mixed glycoprotein B genotypes of cytomegalovirus and immunosuppression.

Crumpacker CS.

Clin Infect Dis. 2004 Jul 15;39(2):162-4. Epub 2004 Jun 23. No abstract available.

PMID:
15307022
20.

Current topics in herpes research.

Crumpacker C.

Herpes. 2003 Dec;10(3):59. No abstract available.

PMID:
14759336
21.

Use of antiviral drugs to prevent herpesvirus transmission.

Crumpacker CS.

N Engl J Med. 2004 Jan 1;350(1):67-8. No abstract available.

PMID:
14702430
22.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2003. A 50-year-old Colombian man with fever and seizures.

Crumpacker CS, Gonzalez RG, Makar RS.

N Engl J Med. 2003 Aug 21;349(8):789-96. No abstract available.

PMID:
12930932
23.

Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA.

Caliendo AM, Yen-Lieberman B, Baptista J, Andersen J, Crumpacker C, Schuurman R, Spector SA, Bremer J, Lurain NS.

J Clin Microbiol. 2003 Aug;41(8):3509-13.

24.

Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.

Weinberg A, Jabs DA, Chou S, Martin BK, Lurain NS, Forman MS, Crumpacker C; Cytomegalovirus Retinitis and Viral Resistance Study Group; Adult AIDS Clinical Trials Group Cytomegalovirus Laboratories.

J Infect Dis. 2003 Mar 1;187(5):777-84. Epub 2003 Feb 24.

PMID:
12599051
25.

A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study.

Dezube BJ, Proper J, Zhang J, Choy VJ, Weeden W, Morrissey J, Burns EM, Dixon JD, O'Loughlin C, Williams LA, Pickering PJ, Crumpacker CS, Gelder FB.

J Infect Dis. 2003 Feb 1;187(3):500-3. Epub 2003 Jan 8.

PMID:
12552435
27.

New anti-HSV therapeutics target the helicase-primase complex.

Crumpacker CS, Schaffer PA.

Nat Med. 2002 Apr;8(4):327-8. No abstract available.

PMID:
11927930
28.

Cocaine enhances myocarditis induced by encephalomyocarditis virus in murine model.

Wang JF, Zhang J, Min JY, Sullivan MF, Crumpacker CS, Abelmann WH, Morgan JP.

Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H956-63.

29.
30.

Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Lurain NS, Weinberg A, Crumpacker CS, Chou S; Adult AIDS Clinical Trials Group-CMV Laboratories.

Antimicrob Agents Chemother. 2001 Oct;45(10):2775-80.

31.

Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma.

Caliendo AM, Schuurman R, Yen-Lieberman B, Spector SA, Andersen J, Manjiry R, Crumpacker C, Lurain NS, Erice A; CMV Working Group of the Complications of HIV Disease RAC, AIDS Clinical Trials Group.

J Clin Microbiol. 2001 Apr;39(4):1334-8.

32.

A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study.

Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Chen LB, Crumpacker CS.

J Infect Dis. 2000 Aug;182(2):607-10. Epub 2000 Jul 28.

PMID:
10915097
33.

Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate.

Oram RJ, Marcellino D, Strauss D, Gustafson E, Talarico CL, Root AK, Sharma PL, Thompson K, Fingeroth JD, Crumpacker C, Herold BC.

J Infect Dis. 2000 Apr;181(4):1458-61. Epub 2000 Apr 13.

PMID:
10762577
34.

Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein.

Zhang JL, Sharma PL, Crumpacker CS.

Virology. 2000 Mar 15;268(2):251-63.

35.

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C.

Antimicrob Agents Chemother. 2000 Mar;44(3):688-92.

37.
38.

Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.

Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT.

Ann Intern Med. 1999 Mar 16;130(6):510-4.

PMID:
10075619
39.

Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.

McSharry JJ, Lurain NS, Drusano GL, Landay AL, Notka M, O'Gorman MR, Weinberg A, Shapiro HM, Reichelderfer PS, Crumpacker CS.

Antimicrob Agents Chemother. 1998 Sep;42(9):2326-31.

40.

Expression of the CD8alpha beta-heterodimer on CD8(+) T lymphocytes in peripheral blood lymphocytes of human immunodeficiency virus- and human immunodeficiency virus+ individuals.

Schmitz JE, Forman MA, Lifton MA, Concepción O, Reimann KA Jr, Crumpacker CS, Daley JF, Gelman RS, Letvin NL.

Blood. 1998 Jul 1;92(1):198-206.

41.

The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry.

Zhang JL, Choe H, Dezube BJ, Farzan M, Sharma PL, Zhou XC, Chen LB, Ono M, Gillies S, Wu Y, Sodroski JG, Crumpacker CS.

Virology. 1998 May 10;244(2):530-41.

42.

Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.

McSharry JM, Lurain NS, Drusano GL, Landay A, Manischewitz J, Nokta M, O'Gorman M, Shapiro HM, Weinberg A, Reichelderfer P, Crumpacker C.

J Clin Microbiol. 1998 Apr;36(4):958-64.

43.

Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.

Gnann JW Jr, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong SJ, Sherrill LC, DeHertogh DA, Whitley RJ.

Antimicrob Agents Chemother. 1998 May;42(5):1139-45.

44.

Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

Sharma PL, Crumpacker CS.

J Virol. 1997 Nov;71(11):8846-51. Erratum in: J Virol 1998 Apr;72(4):3504.

45.

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels.

Dezube BJ, Lederman MM, Chapman B, Georges DL, Dogon AL, Mudido P, Reis-Lishing J, Cheng SL, Silberman SL, Crumpacker CS.

J Infect Dis. 1997 Sep;176(3):807-10.

PMID:
9291340
46.

Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.

Zhang JL, Sharma PL, Li CJ, Dezube BJ, Pardee AB, Crumpacker CS.

Antimicrob Agents Chemother. 1997 May;41(5):977-81.

48.

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.

Balfour HH Jr, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Holm MA, Boivin G, Shepp DH, Crumpacker CS, Eaton CA, Martin-Munley SS.

Antimicrob Agents Chemother. 1996 Dec;40(12):2721-6.

49.

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46.

PMID:
8898668
50.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J.

J Infect Dis. 1996 Oct;174(4):704-12.

PMID:
8843206

Supplemental Content

Loading ...
Support Center